Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

R.P. SCHERER's NEW PRESIDENT AND CEO IS ERNST SCHOEPE following the Nov. 10 resignation of Peter Fink. A member of the board since 1985, Schoepe joined the capsule maker in 1973, most recently serving as VP and chief operating officer until April 1988. Fink's resignation is one of three announced by the company in the aftermath of an unpleasant proxy battle that pitted management against principal shareholder Karla Scherer Fink, the estranged wife of Peter Fink. VP-Finance David Collins and General Counsel W. Merritt Jones also stepped down from their positions. "This is a crucial period for the company ]since[ by unanimous vote the board has agreed to review financial alternatives, including a possible sale of all or part of the company, a recapitalization or a management-led buyout," Fink remarked. "In my judgment, removing myself from an operating and executive role will facilitate and enhance the board's decisionmaking process." Jones is succeeded as corporate general counsel by new board member Theodore Souris, an ally of Karla Fink whose election was hotly contested ("The Pink Sheet" Oct. 10, T&G-5). A successor to Collins has not yet been named. Schoepe resigned as chief operating officer at the end of April just prior to the board's rejection of Karla Fink's proposal to sell the company. Schoepe was one of three board members voting in favor of the proposal, along with Karla Fink and her brother John Scherer. One of the first duties of the realigned board will likely be to elect a new chairman, a slot that has been vacant since the retirement of Wilber Mack at the beginning of October.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts